Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017002 | 0.88 | AHCY (0.61) | AHCYADCY5 | |
| SCHEMBL2017000 | 0.88 | AHCY (0.61) | AHCYADCY5 | |
| SCHEMBL2026537 | 0.82 | AHCY (0.48) | AHCYADCY5 | |
| SCHEMBL13457899 | 0.78 | AHCY (0.39) | AHCYADCY5 | |
| SCHEMBL2015103 | 0.78 | AHCY (0.38) | AHCYADCY5 | |
| SCHEMBL21356436 | 0.66 | ADORA3 (0.50) | ADCY5 | |
| SCHEMBL8885984 | 0.66 | ADORA3 (0.50) | ADCY5 | |
| SCHEMBL8885990 | 0.66 | ADCY5 (0.46) | AHCYADCY5 | |
| SCHEMBL9147328 | 0.65 | ADCY5 (0.64) | AHCYADCY5 | |
| SCHEMBL8883966 | 0.65 | ADORA2A (0.41) | AHCYADCY5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629275-B2 | AHCY hydrolase inhibitors for treatment of hyper homocysteinemia | MERCK SHARP & DOHME CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629275-B2 | AHCY hydrolase inhibitors for treatment of hyper homocysteinemia | MERCK SHARP & DOHME CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629275-B2 | AHCY hydrolase inhibitors for treatment of hyper homocysteinemia | MERCK SHARP & DOHME CORP. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. | 2011-06-30 | — | — | US | disclosed |
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. | 2011-06-30 | — | — | US | disclosed |
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | MERCK SHARP & DOHME CORP. | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160229-A1 | AHCY HYDROLASE INHIBITORS FOR TREATMENT OF HYPER HOMOCYSTEINEMIA | AHCY, AHCYL1, BHMT | AHCY 1/4885ADCY5 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.